VivoSeq
Other

Chronic Fatigue Syndrome

25

Pipeline Programs↗

5

Active Trials↗

14

Companies Involved↗

Chronic Fatigue Syndrome is an emerging landscape with 25 programs across 14 companies. The most active players are Neurocrine Biosciences, Alnylam Pharmaceuticals, Merck & Co.. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

72/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Lundbeck logo

Lundbeck

1 program

Phase 2I

Immunex

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

25 of 27 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody14%Protein / enzyme14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.

Analysis

Trial Status

34

clinical trials

Completed18 · 53%
Terminated4 · 12%
Recruiting4 · 12%
Withdrawn3 · 9%
Unknown status3 · 9%
Temporarily not available1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

34 trials

Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
Recruiting·National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 2·NCT05967052·132 enrolled
Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Recruiting·NNational Center of Neurology and Psychiatry, Japan·Phase 2·NCT06952413·30 enrolled
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Recruiting·NNova Southeastern University·Phase 2·NCT06211062·100 enrolled
The Role of Photobiomodulation in Patients With Chronic Fatigue Syndrome
Recruiting·University of Lahore·Preclinical·NCT07546539·40 enrolled
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04542161·95 enrolled
Autonomic Nervous System and Chronic Fatigue Syndrome
Completed·VVanderbilt University·Phase 1·NCT00580619·170 enrolled
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Completed·AAIM ImmunoTech Inc.·Phase 3·NCT00215800·234 enrolled
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Completed·RRochester Center for Behavioral Medicine·Phase 4·NCT01071044·26 enrolled
Post-COVID-19 Chronic Fatigue Syndrome
Completed·CClinAmygate·Phase 4·NCT05642923·528 enrolled
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Completed·—·Phase 2·NCT03674541·45 enrolled
SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
Completed·IImperial College London·Phase 4·NCT02055898·13 enrolled
Drug Intervention in Chronic Fatigue Syndrome
Completed·HHaukeland University Hospital·Phase 2/3·NCT00848692·30 enrolled
B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
Completed·HHaukeland University Hospital·Phase 3·NCT02229942·151 enrolled
Cytokine Inhibition in Chronic Fatigue Syndrome Patients
Completed·RRadboud University Medical Center·Phase 2/3·NCT02108210·50 enrolled
Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)
Completed·HHaukeland University Hospital·Phase 2·NCT02444091·40 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)